WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317899
CAS#: 80474-14-2
Description: Fluticasone propionate belongs to a class of drugs known as corticosteroids, specifically glucocorticoids, which are hormones that predominantly affect the metabolism of carbohydrates and, to a lesser extent, fat and protein. It is used to treat asthma, allergic rhinitis, nasal polyps, various skin disorders and Crohn's disease and ulcerative colitis. It is also used to treat eosinophilic esophagitis.
Hodoodo Cat#: H317899
Name: Fluticasone Propionate
CAS#: 80474-14-2
Chemical Formula: C25H31F3O5S
Exact Mass: 500.18
Molecular Weight: 500.571
Elemental Analysis: C, 59.99; H, 6.24; F, 11.39; O, 15.98; S, 6.41
Synonym: Fluticasone Propionate, Cutivate, Flixonase, Flixotide, Flonase, Flovent
IUPAC/Chemical Name: (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate
InChi Key: WMWTYOKRWGGJOA-CENSZEJFSA-N
InChi Code: InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
SMILES Code: CCC(O[C@]1(C(SCF)=O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@]3(F)[C@H]2C[C@H](F)C4=CC(C=C[C@@]43C)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 500.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Latorre M, Paggiaro P, Canonica W, Foschino MP, Papi A. A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler. Pulm Pharmacol Ther. 2015 Oct;34:31-6. doi: 10.1016/j.pupt.2015.08.004. Epub 2015 Aug 13. Review. PubMed PMID: 26278189.
2: Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, Demoly P, Devillier P, Hellings P, Fokkens W, Klimek L, Lieberman P, Meltzer E, Price D, Ryan D, Wahn U. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015 Apr;16(6):913-28. doi: 10.1517/14656566.2015.1020789. Epub 2015 Mar 7. Review. PubMed PMID: 25747125.
3: Papi A, Blasi F, Canonica GW, Cazzola M, Centanni S, Foschino Barbaro MP, Melani AS, Paggiaro P, Ricciardolo F, Rossi A, Scichilone N. Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage. Eur J Intern Med. 2014 Oct;25(8):695-700. doi: 10.1016/j.ejim.2014.06.022. Epub 2014 Jul 19. Review. PubMed PMID: 25051902.
4: Restrepo RD, Tate A, Coquat J. Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Oct;14(14):1993-2002. doi: 10.1517/14656566.2013.823949. Epub 2013 Jul 31. Review. PubMed PMID: 23898819.
5: Muley P, Shah M, Muley A. Safety of inhaled fluticasone propionate therapy for pediatric asthma - a systematic review. Curr Drug Saf. 2013 Jul;8(3):186-94. Review. PubMed PMID: 23859431.
6: McKeage K. Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. Drugs. 2013 Feb;73(2):195-206. doi: 10.1007/s40265-013-0016-4. Review. PubMed PMID: 23397367.
7: Steele M, Rosner J. A possible link between fluticasone propionate and tics in pediatric asthmatics. Can J Neurol Sci. 2012 Nov;39(6):851. Review. PubMed PMID: 23230619.
8: Azelastine/fluticasone propionate(Dymista) for seasonal allergic rhinitis. Med Lett Drugs Ther. 2012 Oct 29;54(1402):85-7. Review. PubMed PMID: 23114738.
9: Korting HC, Schöllmann C. Topical fluticasone propionate: intervention and maintenance treatment options of atopic dermatitis based on a high therapeutic index. J Eur Acad Dermatol Venereol. 2012 Feb;26(2):133-40. doi: 10.1111/j.1468-3083.2011.04195.x. Epub 2011 Oct 7. Review. PubMed PMID: 21977914.
10: Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010 Jun 3;5:165-78. Review. PubMed PMID: 20631816; PubMed Central PMCID: PMC2898089.
11: McKeage K, Keam SJ. Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2009;69(13):1799-828. doi: 10.2165/11202210-000000000-00000. Review. PubMed PMID: 19719334.
12: Keating GM, McCormack PL. Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs. 2007;67(16):2383-405. Review. PubMed PMID: 17983257.
13: Li HT, Zhang TT, Zhou H, Qu XJ, Wu WM, Huang J. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. Respiration. 2007;74(1):33-43. Epub 2006 Sep 27. Review. PubMed PMID: 17008769.
14: Sagara H. [Right and wrong of salmeterol/fluticasone propionate combination]. Arerugi. 2006 Jul;55(7):794-810. Review. Japanese. PubMed PMID: 16883107.
15: Masoli M, Weatherall M, Holt S, Shirtcliffe P, Beasley R. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006 Nov;28(5):960-7. Epub 2006 May 31. Review. PubMed PMID: 16737984.
16: Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2005;65(12):1715-34. Review. PubMed PMID: 16060707.
17: Bartkowiak-Emeryk M, Breborowicz A, Emeryk A, Kulus M, Kurzawa R, Lis G, Mazurek H, Niedziela M. [Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part I. Mechanisms of actions and clinical effectiveness of treatment in children with asthma]. Pol Merkur Lekarski. 2004;17 Suppl 2:5-10. Review. Polish. PubMed PMID: 15688663.
18: Roeder A, Schaller M, Schäfer-Korting M, Korting HC. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol. 2005 Jan-Feb;18(1):3-11. Review. PubMed PMID: 15608497.
19: Dransfield MT, Bailey WC. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. Expert Opin Pharmacother. 2004 Aug;5(8):1815-26. Review. PubMed PMID: 15264996.
20: Lyseng-Williamson KA, Keating GM. Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. Am J Respir Med. 2002;1(4):273-82; discussion 283-4. Review. PubMed PMID: 14720047.
